Patterns of company misconduct, recidivism, and complaint resolution delays: A temporal analysis of UK pharmaceutical industry self‐regulation within the European context

Shai Mulinari, Dylan Pashley and Piotr Ozieranski

Regulation & Governance, 2025, vol. 19, issue 1, 200-217

Abstract: Interfirm self‐regulation through trade associations is common but its effectiveness is debated and likely varies by time, country, and industry. This study examines self‐regulation of pharmaceutical marketing, characterized by delegation of major regulatory responsibilities to trade associations' self‐regulatory bodies. In addressing critical research gaps, this study first analyzes 1,776 complaints against pharmaceutical companies in the UK over 18 years (2004–2021). Findings regarding severe, repeat, and complex offending, and delays in complaint resolution raise significant concerns about the adequacy of UK's self‐regulation in deterring wrongdoing. Second, the study conducts international comparisons using recent complaints data from 30 European pharmaceutical industry self‐regulatory bodies. Despite shortcomings of UK's self‐regulation, it appears more adept at identifying potential breaches compared to most other countries, suggesting significant underdetection or underreporting of drug company misconduct in Europe. On balance, our findings are concerning given the negative effects of poorly regulated pharmaceutical marketing on medical practice and health.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1111/rego.12609

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:reggov:v:19:y:2025:i:1:p:200-217

Access Statistics for this article

More articles in Regulation & Governance from John Wiley & Sons
Bibliographic data for series maintained by Wiley Content Delivery ().